Plain-English translation of NCT03677141 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lymphoma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial examined whether , a new type of antibody medication, could work better when combined with chemotherapy drugs to treat B-cell lymphoma. Researchers tested this medication in two ways: combined with a standard chemotherapy regimen (CHOP), and combined with a different chemotherapy approach plus another antibody drug (). The trial included patients whose lymphoma had returned after previous treatment, as well as patients being treated for the first time.
B-cell lymphoma can be hard to treat, especially when it comes back after initial therapy or doesn't respond to standard chemotherapy. This trial was designed to see if this new medication could improve outcomes by harnessing the immune system in a different way than existing treatments.
Participants received intravenous infusions of the new medication combined with chemotherapy drugs on a regular treatment schedule. The trial had two main phases: an initial safety phase where researchers found the right dose, followed by a larger phase where they tested this dose in newly diagnosed patients. Participants would have had multiple clinic visits for treatment and monitoring, with blood tests and scans to track how well the treatment was working and watch for side effects.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States